Skip to main content

Research Repository

Advanced Search

Development of New Antithrombotic Regimens for Patients with Acute Coronary Syndrome.

Development of New Antithrombotic Regimens for Patients with Acute Coronary Syndrome. Thumbnail


Abstract

Patients with acute coronary syndrome (ACS) require long-term antithrombotic intervention to reduce the risk of further ischemic events; dual antiplatelet therapy with a P2Y12 inhibitor and acetylsalicylic acid (ASA) is the current standard of care. However, pivotal clinical trials report that patients receiving this treatment have a residual risk of approximately 10% for further ischemic events. The development of non-vitamin K antagonist oral anticoagulants (NOACs) has renewed interest in a 'dual pathway' strategy, targeting both the coagulation cascade and platelet component of thrombus formation. In the phase III ATLAS ACS 2 TIMI 51 trial, a 'triple therapy' approach (NOAC plus dual antiplatelet therapy) showed reduced ischemic events with rivaroxaban 2.5 mg twice daily, albeit at an increased risk of bleeding. Two studies have investigated the role of NOACs in combination with a P2Y12 inhibitor, with or without ASA, in reducing bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention; two further studies are underway. Although these trials will help to inform optimal treatment protocols for secondary prevention of ACS, an individualized approach to treatment will be needed, taking account of the high frequency of co-morbid conditions found in this patient population.

Acceptance Date Apr 11, 2019
Publication Date Jun 1, 2019
Publicly Available Date Mar 29, 2024
Journal Clinical Drug Investigation
Print ISSN 1173-2563
Publisher Springer Verlag
Pages 495-502
DOI https://doi.org/10.1007/s40261-019-00769-6
Publisher URL https://doi.org/10.1007/s40261-019-00769-6

Files




Downloadable Citations